News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Igeneon Expands Management Board In 2004


10/19/2005 5:09:38 PM

VIENNA, Austria, Jan. 8 /PRNewswire/ -- igeneon, a biopharmaceutical company focused on cancer immunotherapy, today announced that Dr. Manfred Rudiger has joined igeneon's management board as Chief Operating Officer (COO). He will focus mainly on strategic portfolio and business development, in which capacity he will be involved with the partnering of igeneon's current product candidates and the in-licensing of new product candidates.

"Dr. Rudiger joins us in a very crucial phase of the Company's development. Now that we have our lead product in different Phase III studies and two other products in late Phase I trials we need to ensure the sustainable growth of our portfolio. Dr. Rudiger brings with him valuable experience in the areas of licensing and partnering, and we are pleased to be welcoming him on board in 2004," says Dr. Hans Loibner, igeneon's CEO. "I was attracted by the prospect of playing a leading role in one of the major private biotech companies and one of the clinical leaders in Europe," comments Dr. Manfred Rudiger, designated COO.

Rudiger joins igeneon from the German biotech company Cardion AG, where his most recent position was that of Chief Scientific Officer and as of July 2002 acting CEO as well. In that function he was responsible for a successful deal with F. Hoffmann-La Roche in July, 2003. Rudiger holds a PhD degree in molecular biology and protein chemistry and held an academic position at the Technical University in Braunschweig, Germany.

igeneon is a biopharmaceutical company which focuses on the development of active and passive cancer immunotherapies designed to prevent or delay the development of metastases in cancers of epithelial origin. The company has built up a diversified portfolio. The three lead products, cancer vaccines IGN101 and IGN301 and the humanized monoclonal antibody IGN311, are broadly applicable and currently in clinical trials up to Phase III. igeneon is privately held. Investors include 3i, Novartis Venture Fund and Deutsche Venture Capital. The company is based in Vienna, Austria. For further information, visit http://www.igeneon.com/.

Contact for inquiries: igeneon, Brunner Strasse 69/3, A-1230 Vienna, Austria Ursula Mayer, MBA, Corporate Communications tel. ++43/1/90250 133 mobile ++43 699 18904 133 e mail ursula.mayer@igeneon.com

igeneon

CONTACT: Ursula Mayer, MBA, Corporate Communications of igeneon,+43-1-90250-133, or mobile, +43-699-18904-133, ursula.mayer@igeneon.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES